Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Primary result · Reclassification to normal-weight or overweight BMI categoryResult — go to the resultOdds ratio 22.7 95% CI 7.6–67.9Authors' conclusion
Semaglutide was highly effective in reducing BMI category. While on treatment, most trial participants' BMI improved by at least one category, and >40% reached a category below the obesity threshold.
Study context
- Population
- Adolescents with obesity
- Comparison
- Once-weekly SC semaglutide 2.4 mg vs placebo, plus lifestyle intervention
- Primary endpoint
- Reclassification to a normal-weight or overweight BMI category
- Follow-up
- Week 68
Methodological detailspost hoc analysis, double-blind, phase 3a
- Post hoc analysis
- Double-blind
- Phase 3a
Primary result
As reported in the abstract
Reclassification to normal-weight or overweight BMI category
Odds ratio
22.7
95% CI 7.6–67.9
By group
Semaglutidevs Placebo
OR 22.7 (95% CI 7.6–67.9)
Further findings
| Outcome | Semaglutide | Placebo | OR (95% CI) | |
|---|---|---|---|---|
| Improvement of ≥1 BMI category | 73.7% | 19.0% | 23.5 (9.9–55.5) | |
| 0.050.21520Odds ratio (log scale) |
Proportion in obesity class III
- Semaglutide: decreased from 37.3% to 13.6%; increased with placebo
Original publication
Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity (Silver Spring). Published 9 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →